Epic hires lobbying firm to improve interoperability image

Epic Systems has hired a lobbying firm to work on its interoperability image which has been under fire by critics who say the company's system doesn't work well with others.

Epic hired Card & Associates last month. In its federal lobbying disclosure, the EMR firm says that it’s begun lobbying to “educate members of Congress on the interoperability of Epic’s healthcare information technology.”

"There's been a lot of misinformation out there," A. Bradford Card, the firm's principal, told Politico. "I've had a number of productive meetings with Congress to educate members and staff so they know who Epic is and the great story they have to tell. They are the most interoperable EHR company."

Congressman Phil Gingrey (R-Md.) specifically mentioned called out Epic's apparent lack of interoperability during a July hearing on Capitol Hill. "And Congress has spent, as we all know, something like $24 billion over the past six years buying products to facilitate interoperability only to have the main vendor under the program, Epic, sell closed platforms," Gingrey said during the Energy & Commerce Committee hearing. "Do you believe that the federal government and the taxpayers are getting their money's worth subsidizing products that are supposed to be interoperable but they are not?"

In June, Edmund Billings, MD, chief medical officer at Medsphere Systems, the developer of the OpenVista EHR, also criticized Epic. "While Epic preaches interoperability, it practices non-interoperability and vendor lock," he wrote.

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.